Moderna, in collaboration with MCPHS, offers a unique opportunity for PharmD graduates to gain rapid experience in the pharmaceutical industry. Overall, this fellowship program will provide the training and experiences necessary to prepare the fellow for a career in a competitive pharmaceutical industry. Moderna will be recruiting 3 fellows for the fellowship programs starting in July 2025.

The fellowship programs are:

• Global Regulatory Science: 1 position
• Clinical Safety and Pharmacovigilance: 1 position
• Clinical Development Operations: 1 position

Please see our brochure for additional details.

If you have any questions, please contact us at pharmd.fellowships@modernatx.com.

About Moderna

Moderna is a leader in the creation of the field of messenger RNA (mRNA) medicine. By working at the intersection of science, technology and health for more than a decade, we have developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Our mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, we strive to deliver the greatest possible impact to people through mRNA medicines.

Our first commercial product, Spikevax (our COVID-19 vaccine), has helped hundreds of millions of people worldwide combat COVID-19. SARS-CoV-2, the virus that causes COVID-19, continues to evolve and in 2023, the COVID-19 vaccine market transitioned to an endemic, seasonal commercial market. Our second commercial product, mRESVIA, an RSV vaccine, was approved by the FDA in May 2024.

Having demonstrated clinical benefit in multiple infectious disease areas and skin cancer, as well as potential clinical benefit for several rare genetic diseases, we continue to advance a broad and diverse pipeline and are focused on execution to deliver for patients. Our pipeline includes 47 therapeutic and vaccine programs, nine of which are in late-stage development.

To learn more, visit www.modernatx.com.

Eligibility

The MCPHS Biopharmaceutical Industry fellows will be selected on a nationally competitive basis. Applicants must have a Doctor of Pharmacy degree from an ACPE accredited college of pharmacy at the commencement of the program.

• Candidates must have strong written and verbal communication skills and a strong interest in pursuing a career within the biopharmaceutical industry.
• All candidates must have authorization to work in the United States throughout the duration of the one or two year fellowship. No visa sponsorship will be provided (i.e., TN, H-1B, STEM OPT, etc.).

Application Procedure

To be considered for an interview, please complete a fellowship application on the MCPHS SMApply application portal. Visit https://mcphs.smapply.io/

Please DO NOT request an interview within PPS. Our recruitment teams will contact qualified candidates via email to schedule interviews. 

The MCPHS application portal (SMApply) will open up on Monday, October 7, 2024. Applicants must upload the following application materials to the online portal by Monday, November 4, 2024:

• Letter of intent (addressed to the company specific program director/lead; found in each company brochure)
• Curriculum vitae
• Unofficial college transcript
• Contact information for three references. References will receive an electronic recommendation form to complete separately.

Three recommendation evaluation forms must be submitted no later than November 20, 2024 via the online portal. This is NOT a letter of recommendation but an online form that the recommender will receive for completion from SMApply.

Application Review and Interview Timeline

Following a review of submitted applications, pre-screens and preliminary interviews will begin in October. Additional interviews, including final rounds will take place in December during ASHP. Candidates will be notified if selected for an interview. The process is rigorous and competitive; therefore candidates should submit their applications well in advance of posted deadlines as priority will be given to those who apply early.

ASHP Midyear and  Onsite Interviews

The fellowship program will be conducting in-person interviews at the ASHP Midyear Clinical Meeting in New Orleans, LA. Attendance is strongly encouraged, but not required. Candidates attending in-person will not be able to interview without registering for both ASHP and PPS. Please refer to the ASHP & PPS website for registration details.

Top candidates may be invited for interviews at the sponsoring company’s location.

AIFA First Offer Date

The choice of a Post-Doctoral Fellowship is an important decision. MCPHS, in conjunction with the Alliance of Industry Fellowship Associates (AIFA), has aligned to extend offers for Fellowships no earlier than December 16, 2024. We believe this is a positive reflection of the cultures our Programs offer, and that culture is a critical consideration in choice of Fellowship. We hope that other academic and non-academic Fellowship Programs will NOT pressure candidates to accept offers prior to this aligned offer date.

We see this respect for candidate choice as a common aspect of each of our Program's cultures. We hope that other academic and non-academic Fellowship Programs will respect this timeline.

Learn more about AIFA affiliated programs.

Onboarding

Final candidates will be required to go through additional screening / onboarding as required by MCPHS.

About MCPHS/Moderna

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past eight years. To learn more, visit www.modernatx.com.

Connections working at MCPHS/Moderna